Kala Bio (KALA) Debt Ratio (2016 - 2025)

Kala Bio (KALA) posted Debt Ratio of 1.14 for Q3 2025, up 44.67% sequentially from 0.78 in Q2 2025, and up 74.75% YoY from 0.65 in Q3 2024.

Kala Bio (KALA) Debt Ratio (2016 - 2025) Analysis & Trends

Kala Bio has reported Debt Ratio for 10 years, with the latest figure at 1.14 in Q3 2025.

Quarterly Debt Ratio rose 74.75% year-over-year to 1.14 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 1.14 (up 74.75% YoY) and the FY2024 annual result came in at 0.55, down 10.23% from the prior year.
Debt Ratio improved to 1.14 in Q3 2025 per KALA's latest filing, from 0.78 in the prior quarter.
Over five years, Debt Ratio peaked at 1.14 in Q3 2025 and troughed at 0.32 in Q1 2021.
A 5-year average of 0.61 and a median of 0.57 in 2024 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2022 and 2023: Debt Ratio jumped 171.48% in 2022, then tumbled 48.67% in 2023.
Over 5 years, Debt Ratio stood at 0.59 in 2021, then dropped by 18.33% to 0.48 in 2022, then gained by 26.07% to 0.61 in 2023, then retreated by 10.23% to 0.55 in 2024, then jumped by 106.98% to 1.14 in 2025.
According to Business Quant data, Debt Ratio over the past three periods registered 1.14, 0.78, and 0.63 for Q3 2025, Q2 2025, and Q1 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.05
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.26
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.47
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.03
10	Kala Bio	9.87 Mn	9.87 Mn	-	-

Download Data